279252-26-5

Basic information

• Product Name: 2-Chloro-4-(trifluoromethyl)benzyl bromide
• Synonyms: 2-Chloro-4-(trifluoromethyl)benzyl bromide;1-(bromomethyl)-2-chloro-4-(trifluoromethyl)benzene;BENZENE, 1-(BROMOMETHYL)-2-CHLORO-4-(TRIFLUOROMETHYL)-
• CAS NO: 279252-26-5
• Molecular Formula: C₈H₅BrClF₃
• Molecular Weight: 273.4775096
• Mol File: 279252-26-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Chloro-4-(trifluoromethyl)benzyl bromide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-(trifluoromethyl)benzyl bromide(279252-26-5)
• EPA Substance Registry System: 2-Chloro-4-(trifluoromethyl)benzyl bromide(279252-26-5)

Safety Data

• Hazardous Substances Data: 279252-26-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-Chloro-4-(trifluoromethyl)benzyl bromide is used as a reagent in organic synthesis for introducing the benzyl bromide functional group into various organic molecules. Its presence allows for further chemical reactions and modifications, making it a valuable component in the synthesis of complex organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Chloro-4-(trifluoromethyl)benzyl bromide is used as an intermediate in the synthesis of certain pharmaceutical compounds. Its unique structure and reactivity enable the creation of new drug candidates with potential therapeutic applications.
Used in Chemical Research:
2-Chloro-4-(trifluoromethyl)benzyl bromide is also utilized in chemical research as a model compound to study the effects of chloro and trifluoromethyl groups on the reactivity and properties of benzene derivatives. This helps researchers understand the underlying chemical principles and develop new synthetic strategies.
It is crucial to handle 2-Chloro-4-(trifluoromethyl)benzyl bromide with care due to its potential to cause skin, eye, and respiratory irritation, as well as its flammability and reactivity with water. Proper safety protocols and protective equipment should be employed to minimize the risk of exposure and accidents.

Upstream product

• 56456-51-0 (2-chloro-4-(trifluoromethyl)phenyl)methanol 
• 74483-47-9 2-Chloro-4-(trifluoromethyl)toluene 
• 135049-84-2 4-bromomethyl-3-chloroiodobenzene 
• 558-13-4 carbon tetrabromide 

Downstream Products

• 888739-48-8 ethyl 3-{1-[2-chloro-4-(trifluoromethyl)benzyl]-3-isopropoxy-1H-pyrazol-5-yl}propanoate 
• 219768-33-9 3-(2-Chloro-4-trifluoromethylbenzyl)-2,7-dimethyl-3H-imidazo[4,5-b]pyridine-5-carboxylic acid 

Relevant articles and documents

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the formula (I): wherein Ar is an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1 and Z2 are each a bond, O, S, -CO-, -CS-, - CR3 (OR4) -, -NR5-, -SO-, -SO2-, -CONR6- or -NR6CO- (wherein R3, R4, R5 and R6 are as defined in the specification); Xb and Yb are each a bond or a divalent hydrocarbon group having 1 to 20 carbon atoms; R1 is an optionally substituted hydrocarbon group; ring A is an optionally further substituted aromatic ring, provided that the ring should not be benzimidazole; n is an integer of 1 to 8; ring B is an optionally further substituted aromatic ring, provided that the ring should not be oxazole; W is a divalent saturated hydrocarbon group having 1 to 20 carbon atoms; and R2 is -OR8 or -NR9R10 (wherein R8, R9 and R10 are as defined in the specification) or a salt thereof, is useful as an agent for the prophylaxis or treatment of diabetes and the like.

THERAPEUTIC AGENT FOR DIABETES

The present invention provides an agent for the prophylaxis or treatment of diabetes, which is associated with a ferwer side effects such as body weight gain, adipocyte accumulation, cardiac hypertrophy and the like, and which contains a compound represented by the formula: wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

ARYLALKANOIC ACID DERIVATIVE

A compound represented by the general formula (I): [wherein Ar represents an optionally substituted aromatic ring; Xa, Xc, Ya, Yc, Z1, and Z2 each represents a bond, O, S, -CO-, -CS-, -CR3(OR4)-, -NR5-, -SO-, -SO2-, -CONR6-, or -NR6CO- (R3, R4, R5, and R6 are as defined in the description); Xb and Yb each represents a bond or a C1-20 divalent hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; ring A represents an aromatic ring (other than benzimidazole) which may be further substituted; n is an integer of 1-8; ring B represents an aromatic ring (other than oxazole) which may be further substituted; W represents a C1-20 divalent saturated hydrocarbon group; and R2 represents -OR8 or -NR9R10 (R8, R9, and R10 are as defined in the description)] or a salt of the compound. It is useful as a preventive/therapeutic agent for diabetes, etc.

IMIDAZOLE COMPOUNDS AND MEDICINAL USE THEREOF

Imidazole compounds represented by general formula (I): wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy inhibitory action.

BENZIMIDAZOLE DERIVATIVES

The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: wherein R1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group: R2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 8 carbon atoms, an aryl group, and such; R3 represents a lower alkyl group, a lower alkenyl group, an aryl group, a lower alkylaryl group, an aryl-lower alkenyl group, a halothienyl group, a lower alkylamino group, or an aryl-lower alkylamino group; A represents a benzene ring, a naphthalene ring, or a pyridine ring; and X represents a halogen atom. The derivatives and their salts have blood sugar level-depressing activity or PDE5-inhibiting activity, and are useful as pharmaceutical preparations.